Cyclophosphamide is an alkylating agent widely used in clinical oncology in both conventional and high-dose chemotherapy regimens. It has been shown that large interindividual variation in clinical effect exist with cyclophosphamide treatment and it has been proposed that these varied responses (both efficacy and toxicity) may reflect interpatient differences in metabolism and distribution of the drug ([Huitema *et al*, 2002](#bib11){ref-type="other"}). However, relationships between the pharmacokinetics of cyclophosphamide and its biological effects are incompletely understood. This is partly explained by the complex metabolic profile of cyclophosphamide ([Figure 1](#fig1){ref-type="fig"}) and incomplete understanding of which compounds are involved in clinical response and toxicity.

Cyclophosphamide itself is an inactive prodrug. Approximately 70--80% of the administered drug is bioactivated by cytochrome *P*450 enzymes to form 4-hydroxycyclophosphamide. 4-Hydroxycyclophosphamide is unstable and decomposes into phosphoramide mustard, the ultimate alkylating metabolite. In contrast to 4-hydroxycyclophosphamide, phosphoramide mustard cannot enter target cells, and therefore only the intracellularly formed phosphoramide mustard fraction is considered to be cytotoxic. Plasma concentrations of 4-hydroxycyclophosphamide are therefore a good marker of the alkylating activity of cyclophosphamide ([De Jonge *et al*, 2005](#bib5){ref-type="other"}).

The dose-limiting toxicity of cyclophosphamide at conventional doses is myelosuppression, primarily leukopenia. In the setting of bone marrow transplantation, where higher cyclophosphamide doses can be used, the toxicity profile of cyclophosphamide includes haemorrhagic cystitis, hepatic damage (veno-occlusive disease of the liver (VOD)) pulmonary toxicity and cardiac necrosis ([Fraiser *et al*, 1991](#bib7){ref-type="other"}). Several authors have reported weak relationships between exposure or clearance of cyclophosphamide and its efficacy and toxicity ([Ayash *et al*, 1992](#bib2){ref-type="other"}; [Nieto *et al*, 1999](#bib18){ref-type="other"}; [Petros *et al*, 2002](#bib19){ref-type="other"}; [Yule *et al*, 2004](#bib29){ref-type="other"}). However, few studies have focused on relationships between exposure to cyclophosphamide metabolites and the occurrence of toxicity or efficacy. An indication for a correlation between high exposures to 4-hydroxycyclophosphamide or phosphoramide mustard and the occurrence of VOD was given in three different studies ([Honjo *et al*, 1988](#bib9){ref-type="other"}; [Ren and Slattery, 1999](#bib20){ref-type="other"}; [Huitema *et al*, 2002](#bib11){ref-type="other"}). High exposures to the inactive carboxyphosphamide have also been related to increased incidence of VOD ([McDonald *et al*, 2003](#bib16){ref-type="other"}), which was explained by a positive correlation between 4-hydroxycyclophosphamide and carboxyphosphamide formation.

Veno-occlusive disease of the liver is a life-threatening complication of myeloablative regimens ([Shulman *et al*, 1980](#bib27){ref-type="other"}; [Ayash *et al*, 1990](#bib1){ref-type="other"}; [Nevill *et al*, 1991](#bib17){ref-type="other"}; [McDonald *et al*, 1993](#bib15){ref-type="other"}, [2003](#bib16){ref-type="other"}). Therefore, we investigated whether a significant relationship could be found between exposures to 4-hydroxycyclophosphamide and phosphoramide mustard and the occurrence of VOD.

PATIENTS AND METHODS
====================

Patients and treatment
----------------------

Patients received the cyclophosphamide, thiotepa and carboplatin (CTC) high-dose chemotherapy regimen with peripheral blood progenitor cell transplantation as described previously ([Rodenhuis *et al*, 1996](#bib24){ref-type="other"}, [1998](#bib23){ref-type="other"}, [1999](#bib22){ref-type="other"}, [2003](#bib21){ref-type="other"}; [Schrama *et al*, 2001](#bib25){ref-type="other"}). Patients had either high-risk primary breast cancer and received high-dose chemotherapy as part of their adjuvant treatment, or had advanced breast, germ-cell or ovarian cancer.

Two different high-dose CTC schedules were used. The full-dose CTC regimen consisted of 4 days of chemotherapy with cyclophosphamide (1500 mg m^−2^ day^−1^) as a 1 h infusion, immediately followed by carboplatin (400 mg m^−2^ day^−1^) as a daily 1 h infusion, and thiotepa (120 mg m^−2^ day^−1^) divided over two 30-min infusions (the second daily dose of TT was administered 12 h after the first dose) ([Rodenhuis *et al*, 1998](#bib23){ref-type="other"}, [2003](#bib21){ref-type="other"}). The 'tiny\' CTC regimen (tCTC) was identical to the CTC regimen except that it incorporated 2/3rd of the dose of each agent ([Rodenhuis *et al*, 1996](#bib24){ref-type="other"}, [1999](#bib22){ref-type="other"}; [Schrama *et al*, 2001](#bib25){ref-type="other"}). Patients received either one (high-risk primary breast cancer) or two (refractory germ-cell cancer) courses of CTC or two (metastatic ovarian cancer) or three (metastatic breast or relapsing germ-cell cancer) courses of tCTC, when possible every 4 weeks. Full details of the CTC and tCTC regimens have been published previously ([Rodenhuis *et al*, 1996](#bib24){ref-type="other"}, [1998](#bib23){ref-type="other"}, [1999](#bib22){ref-type="other"}, [2003](#bib21){ref-type="other"}; [Schrama *et al*, 2001](#bib25){ref-type="other"}).

All protocols were approved by the Committee of Medical Ethics of the Netherlands Cancer Institute and written informed consent was obtained from all patients.

Sampling and analysis
---------------------

During the 4-day CTC course, blood samples were collected from a double lumen catheter inserted in a subclavian vein. Complete pharmacokinetic profiles were assessed on two separate days, always including day 1 and either day 3 or 4. Samples were taken at 30 min after the start of CP infusion and at 60 (end of CP infusion), 90, 120 (end of carboplatin infusion), 150 (end of TT infusion), 165, 180, 210, 285, 390 and 660 min. On day 5, an additional sample was collected approximately 22 h after the last CP infusion. A total of approximately 21 samples were available per patient per course. Sample pretreatment and bioanalysis of cyclophosphamide, 4-hydroxycyclophosphamide, phosphoramide mustard, thiotepa, tepa and carboplatin were conducted as described previously ([Van Warmerdam *et al*, 1995](#bib28){ref-type="other"}; [Huitema *et al*, 1998](#bib12){ref-type="other"}, [2000a](#bib13){ref-type="other"}, [2000b](#bib14){ref-type="other"}).

Pharmacokinetic analysis
------------------------

Pharmacokinetic calculations for cyclophosphamide, 4-hydroxycyclophosphamide and phosphoramide mustard were performed based on two population pharmacokinetic models previously developed in our institute ([Huitema *et al*, 2001](#bib10){ref-type="other"}; [De Jonge *et al*, 2004](#bib4){ref-type="other"}) using the nonlinear mixed effect modelling program NONMEM (double precision, version V 1.1) ([Beal and Sheiner, 1998](#bib3){ref-type="other"}). The applied model is schematically depicted in [Figure 2](#fig2){ref-type="fig"}. Parameters were estimated using data of all patients included in the present study. In brief, the model includes both the recognised autoinduction process of cyclophosphamide resulting in increased rate of 4-hydroxycyclophosphamide and phosphoramide mustard formation in time, as well as the inhibitory effect of thiotepa on this induction. For more details on the model we refer to earlier publications ([Huitema *et al*, 2001](#bib10){ref-type="other"}; [De Jonge *et al*, 2004](#bib4){ref-type="other"}).

Based on measured plasma concentrations in the individuals included in this study and the population pharmacokinetic model as presented in [Figure 2](#fig2){ref-type="fig"}, Bayesian estimates of the area under the plasma concentration--time curves (AUCs) of 4-hydroxycyclophosphamide and phosphoramide mustard were generated. These estimates were obtained with the POSTHOC option of NONMEM taking both the population pharmacokinetic parameters and the individual data into account ([Beal and Sheiner, 1998](#bib3){ref-type="other"}). AUCs of thiotepa, tepa and carboplatin were calculated in a similar way using previously developed population pharmacokinetic models ([Huitema *et al*, 2002](#bib11){ref-type="other"}; [De Jonge *et al*, 2004](#bib4){ref-type="other"}).

Clinical diagnosis of VOD
-------------------------

The clinical diagnosis VOD was based on the occurrence of two of the following events within 20 days of transplantation: hyperbilirubinemia (total serum bilirubin \>34.2 *μ*mol l^−1^), hepatomegaly (or right upper quadrant pain of liver origin) and ascites ([Ayash *et al*, 1990](#bib1){ref-type="other"}; [McDonald *et al*, 1993](#bib15){ref-type="other"}). The occurrence of VOD was registered in a dichotomous (e.g. no VOD or VOD) way.

Statistical analysis
--------------------

Relationships between VOD, occurring after multiple courses, and the cumulative AUCs of 4-hydroxycyclophosphamide and phosphoramide mustard were tested using logistic regression. Also other possible determinants of VOD (exposure to thiotepa and its metabolite tepa, carboplatin exposure or cisplatin pretreatment) were tested in an univariate and subsequently multivariate way. In order to assess whether the AUC of the first course is a prognostic factor for toxicity after subsequent courses, logistic regression was used with both the AUC of the first course and the number of courses administered.

Significance of the logistic regression models was assessed with the Wald statistic. The Statistical Service Solution for Windows version 11.0 (SPSS Inc., Chicago, IL, USA) was used and a two-sided significance level of 0.05 was used for all tests.

RESULTS
=======

Data were available from a total number of 59 patients (115 courses). In [Table 1](#tbl1){ref-type="table"}, the details of the patient population and treatment are summarised. In the first 32 patients (57 courses) pharmacokinetic data were available for cyclophosphamide, 4-hydroxycyclophosphamide, thiotepa, tepa and carboplatin, while in the final 27 patients (58 courses) also data of phosphoramide mustard were available.

A total of four patients experienced VOD. Three patients with refractory germ-cell cancer developed VOD after a second CTC course. One patient, treated for metastatic breast cancer developed VOD after a second tCTC course. Of this latter patient, no phosphoramide mustard data were available for both courses.

[Figure 3A and B](#fig3){ref-type="fig"} shows a comparison of the AUC of 4-hydroxycyclophosphamide and phosphoramide mustard during the first course between patients with and without VOD. A significant relationship between the first course AUC of 4-hydroxycyclophosphamide and the occurrence of VOD was found (*P*=0.003) while no significant relationship was found between the first course phosphoramide mustard AUC and VOD (*P*=0.101). Mean AUC of 4-hydroxycyclophosphamide in the first course was 134.5 *μ*[M]{.smallcaps} h in the patients without VOD and 184.5 *μ*[M]{.smallcaps} h^−1^ in the patients with VOD. For phosphoramide mustard, the mean first course exposure was 526.7 *μ*[M]{.smallcaps} h^−1^ in the patients without VOD and 792.0 *μ*[M]{.smallcaps} h^−1^ in the patients with VOD. From these results it can be concluded that the exposure to 4-hydroxycyclophosphamide is predictive for hepatic damage after following courses.

No significant relationship was found between the total cumulative 4-hydroxycyclophosphamide or phosphoramide mustard AUC and the occurrence of VOD (*P*=0.173 and 0.428, respectively) in patients receiving two or more courses. Other possible determinants of VOD (exposure to thiotepa and tepa, carboplatin exposure or cisplatin pretreatment) did not result in significant relationships.

DISCUSSION
==========

The goal of this study was to assess the impact of exposure to bioactivated cyclophosphamide on the occurrence of VOD caused by the high-dose CTC chemotherapy regimen. We found that increased exposures to 4-hydroxycyclophosphamide in course one led to increased occurrence of VOD. Despite the low incidence of VOD (four out of 59 patients developed VOD), statistically significant conclusions could be drawn.

Hepatic injury resulting from treatment with high-dose cyclophosphamide has been reported to be cyclophosphamide dose related ([Honjo *et al*, 1988](#bib9){ref-type="other"}) and may be caused by acrolein which is a by-product in the bioactivation of cyclophosphamide ([Figure 1](#fig1){ref-type="fig"}). Acrolein may cause liver dysfunction by binding to cytochrome enzymes, hepatic macromolecules and nucleic acids ([DeLeve, 1996](#bib6){ref-type="other"}). Inhibition of hepatic glutathione-*S*-transferase by acrolein ([Scott and Kirsch, 1988](#bib26){ref-type="other"}), as well as direct glutathione depletion ([DeLeve, 1996](#bib6){ref-type="other"}), may cause acrolein accumulation in the liver after administration of high doses of cyclophosphamide. High-dose busulphan may also cause a depletion of glutathione and glutathione-*S*-transferase levels ([Hassan *et al*, 2000](#bib8){ref-type="other"}). Therefore, the combination cyclophosphamide/busulphan, regularly used in the bone marrow transplantation setting, is often complicated by hepatic toxicity ([Nevill *et al*, 1991](#bib17){ref-type="other"}; [McDonald *et al*, 1993](#bib15){ref-type="other"}).

Our results indicate that the exposure intensity to 4-hydroxycyclophosphamide during treatment may be important in the development of VOD. Higher exposures to 4-hydroxycyclophosphamide in the first course were indicative of the occurrence of VOD later on, possibly because of liver damage not fully recovered before administration of a next similar course (with intrapatient AUC variation between courses of treatment being 23%). Total cumulative exposure to 4-hydroxycyclophosphamide after multiple courses, however, was not significantly correlated, although a trend was observed. This is exemplified by the fact that patients treated with three courses of tCTC received in total the same cyclophosphamide dose as patients receiving two courses of CTC. However, VOD never occurred after 3rd courses of tCTC (in total 19 patients) but occurred in three of the 10 patients receiving two courses of full-dose CTC. Increased risk for VOD in the CTC patients, compared with the tCTC patients, may therefore be explained by administration of a similar total exposure in a shorter time period. From these results it can be concluded that patients receiving a higher exposure intensity to 4-hydroxycyclophosphamide are more likely to develop hepatic damage.

In conclusion, a relationship between the occurrence of VOD and pharmacokinetics of cyclophosphamide has been established. This result indicates that the incidence of VOD may be reduced with lower cyclophosphamide dose intensity or individualised dosing of cyclophosphamide. Therapeutic drug monitoring may be useful for adjusting a cyclophosphamide dose to target the 4-hydroxycyclophosphamide exposure to a value consistent with low toxicity.
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![Population pharmacokinetic model of cyclophosphamide (CP) and its metabolites 4-hydroxycyclophosphamide (4OHCP) and phosphoramide mustard (PM).](94-6603097f2){#fig2}

![Area under the plasma concentration--time curves (AUCs) of (**A**) 4-hydroxycyclophosphamide and (**B**) phosphoramide mustard of patients with VOD (developed after subsequent courses) *vs* the remaining population, with -- being the mean of the data points.](94-6603097f3){#fig3}

###### 

Patients and treatment

  **Disease**                       **Regimen**   **Number of patients**   **Number of courses**   **Number of 1st courses**   **Number of 2nd courses**   **Number of 3rd courses**
  --------------------------------- ------------- ------------------------ ----------------------- --------------------------- --------------------------- ---------------------------
  High risk primary breast cancer   1 CTC         16                       16                      16                                                       
  Metastatic breast cancer          3 tCTC        25                       63                      25                          21                          17
  Refractory germ cell cancer       2 CTC         10                       20                      10                          10                           
  Refractory germ-cell cancer       3 tCTC        3                        8                       3                           3                           2
  Metastatic ovarian cancer         2 tCTC        5                        8                       5                           3                            
                                                                                                                                                            
  Total                                           59                       115                     59                          37                          19
